Kerstin Papenfuss started her PhD at German Cancer Research Centre and Imperial College to work on novel treatment options within the field of tumour immunology. She has since spent more than ten years in leadership roles at impact-driven organisations advancing medicine and therapeutics inducing LifeArc and the Cell and Gene Therapy Catapult, while also securing an executive MBA and women in business award. Since joining DSV, she has been developing science companies designing more effective therapies as well as managing the pharma portfolio.